person · Reporting owner

MCGLYNN MARGARET G

Disclosed activity across 4 companies

Tapewire entity: 15358
SEC CIK: 0001215126

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Air Products & Chemicals, Inc.APD · Entity 2983	Director	September 30, 2020	October 01, 2020
NOVAVAX INCNVAX · Entity 4632	Director	June 18, 2026	June 23, 2026
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875	Director	May 01, 2023	May 03, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Air Products & Chemicals, Inc.

Report date September 30, 2020 · Filed October 01, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	42,813.6292	Reported balance After 2020-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-09-30 · Grant · Acquired 194.3437 · Balance 42,813.6292 F1: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan. F2: Not applicable to this security F3: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance.

Filing footnotes · ownership attribution and instrument terms

F1: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan.

F2: Not applicable to this security

F3: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance.

NOVAVAX INC

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	44,468	Reported balance After 2026-06-20 transaction · row 1 1 source row Row 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 44,468 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18	Direct	21,270	Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	14,180	Reported balance After 2026-06-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.

F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.

F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date

VERTEX PHARMACEUTICALS INC / MA

Report date May 01, 2023 · Filed May 03, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $342.73 · Expires 2033-04-30	Direct	3,481	Reported balance After 2023-05-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-05-01 · Grant · Acquired 3,481 · Balance 3,481 F1: Fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: Fully vested.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMICUS THERAPEUTICS, INC.

Report date April 27, 2026 · Filed April 27, 2026

Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-04-27 transaction · row 1 1 source row Row 1 · 2026-04-27 · Disposition to issuer · Disposed 94,631 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 31,000 shares of Common Stock and 63,631 restricted stock units (which vested in full in connection with consummation of the Merger).
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2026-06-09	Direct	Reported balance After 2026-04-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2027-06-13	Direct	Reported balance After 2026-04-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-27 · Disposition to issuer · Disposed 16,236 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2029-06-27	Direct	Reported balance After 2026-04-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-27 · Disposition to issuer · Disposed 19,473 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04	Direct	Reported balance After 2026-04-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-04-27 · Disposition to issuer · Disposed 18,574 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10	Direct	Reported balance After 2026-04-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-04-27 · Disposition to issuer · Disposed 36,111 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09	Direct	Reported balance After 2026-04-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08	Direct	Reported balance After 2026-04-27 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06	Direct	Reported balance After 2026-04-27 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05	Direct	Reported balance After 2026-04-27 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 31,000 shares of Common Stock and 63,631 restricted stock units (which vested in full in connection with consummation of the Merger).

F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.

F3: Each Option was fully vested.

F4: Each Option vested in full in connection with consummation of the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 09, 2022 Filed Jun 10, 2022 20:09 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	45,423	$0.00 Strike: $8.55	$0.00	Disclosure SEC source: 0001209191-22-035836 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,423 Underlying: Common Stock · 45,423 shares Expires 2032-06-09 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:09 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	12,671	$0.00	$0.00	Disclosure SEC source: 0001209191-22-035836 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,705 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document
May 02, 2022 Filed May 4, 2022 23:37 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Disposition to issuerStock Options (right to buy) · Derivative	15,000	$0.00 Strike: $4.79	$0.00	Disclosure SEC source: 0001209191-22-027245 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-06-13 F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document
May 02, 2022 Filed May 4, 2022 23:37 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	SaleCommon Stock	15,000	$6.99	$104,896.50	Disclosure SEC source: 0001209191-22-027245 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,034 F1 · kind: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $6.83 to $7.16 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 02, 2022 Filed May 4, 2022 23:37 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	15,000	$4.79	$71,850.00	Disclosure SEC source: 0001209191-22-027245 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2022 Filed May 3, 2022 20:47 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantStock Option (Right to Buy) · Derivative	4,462	$0.00 Strike: $276.17	$0.00	Disclosure SEC source: 0000899243-22-016336 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,462 Underlying: Common Stock · 4,462 shares Expires 2032-04-30 Read SEC document
May 01, 2022 Filed May 3, 2022 20:47 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantDeferred Stock Units · Derivative	921	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-016336 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,609 Underlying: Common Stock · 921 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McGlynn's disability or death. F1 · price: Upon the vesting of restricted stock units granted to Ms. McGlynn on May 1, 2021, Ms. McGlynn deferred the receipt of 921 shares of common stock and received instead 921 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 921 shares of common stock in exchange for an equal number of deferred stock units. F2 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McGlynn's disability or death. F2 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McGlynn's disability or death. Read SEC document
May 01, 2022 Filed May 3, 2022 20:47 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Disposition to issuerCommon Stock	921	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-016336 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178 F1 · price: Upon the vesting of restricted stock units granted to Ms. McGlynn on May 1, 2021, Ms. McGlynn deferred the receipt of 921 shares of common stock and received instead 921 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 921 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document
April 08, 2022 Filed Apr 12, 2022 20:05 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $127.54	$0.00	Disclosure SEC source: 0000899243-22-014548 · doc4.xml · derivative · entry 4 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document
April 08, 2022 Filed Apr 12, 2022 20:05 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	100	$281.49	$28,149.00	Disclosure SEC source: 0000899243-22-014548 · doc4.xml · nonDerivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,099 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. Read SEC document
April 08, 2022 Filed Apr 12, 2022 20:05 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	4,900	$280.19	$1,372,931.00	Disclosure SEC source: 0000899243-22-014548 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,199 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F2 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $280.19 (range $280.00 to $280.95). Read SEC document
April 08, 2022 Filed Apr 12, 2022 20:05 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	5,000	$127.54	$637,700.00	Disclosure SEC source: 0000899243-22-014548 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 31, 2022 Filed Apr 4, 2022 20:05 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock (right to buy) · Derivative	5,000	$127.54 Strike: $127.54	$637,700.00	Disclosure SEC source: 0000899243-22-013305 · doc4.xml · derivative · entry 5 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2025-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested Read SEC document
March 31, 2022 Filed Apr 4, 2022 20:05 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,011	$262.97	$265,862.67	Disclosure SEC source: 0000899243-22-013305 · doc4.xml · nonDerivative · entry 4 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,099 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $262.97 (range $262.80 to $263.34). Read SEC document
March 31, 2022 Filed Apr 4, 2022 20:05 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	2,970	$262.37	$779,238.90	Disclosure SEC source: 0000899243-22-013305 · doc4.xml · nonDerivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,110 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $262.37 (range $261.79 to $262.78). Read SEC document
March 31, 2022 Filed Apr 4, 2022 20:05 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,019	$261.28	$266,244.32	Disclosure SEC source: 0000899243-22-013305 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,080 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $261.28 (range $260.78 to $261.73). F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
March 31, 2022 Filed Apr 4, 2022 20:05 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	5,000	$127.54	$637,700.00	Disclosure SEC source: 0000899243-22-013305 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 28, 2022 Filed Feb 1, 2022 21:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$127.54 Strike: $127.54	$637,700.00	Disclosure SEC source: 0001209191-22-005895 · doc4.xml · derivative · entry 6 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires 2025-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document
January 28, 2022 Filed Feb 1, 2022 21:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	212	$243.24	$51,566.88	Disclosure SEC source: 0001209191-22-005895 · doc4.xml · nonDerivative · entry 5 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,099 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $243.24 (range $243.21 to $243.27). Read SEC document
January 28, 2022 Filed Feb 1, 2022 21:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	2,087	$242.78	$506,681.86	Disclosure SEC source: 0001209191-22-005895 · doc4.xml · nonDerivative · entry 4 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,311 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $242.78 (range $242.18 to $243.14). Read SEC document
January 28, 2022 Filed Feb 1, 2022 21:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	800	$241.83	$193,464.00	Disclosure SEC source: 0001209191-22-005895 · doc4.xml · nonDerivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,398 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $241.83 (range $241.16 to $242.15). Read SEC document
January 28, 2022 Filed Feb 1, 2022 21:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,901	$240.53	$457,247.53	Disclosure SEC source: 0001209191-22-005895 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,198 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $240.53 (range $240.01 to $240.92). F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
January 28, 2022 Filed Feb 1, 2022 21:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	5,000	$127.54	$637,700.00	Disclosure SEC source: 0001209191-22-005895 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 17, 2021 Filed Jun 22, 2021 21:19 UTC	NOVAVAX INC NVAX · Entity 4632	GrantRestricted Stock Units · Derivative	700	$0.00	$0.00	Disclosure SEC source: 0001209191-21-042455 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 Underlying: Common Stock · 700 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document
June 17, 2021 Filed Jun 22, 2021 21:19 UTC	NOVAVAX INC NVAX · Entity 4632	GrantStock Option (Right to Buy) · Derivative	1,300	$0.00 Strike: $179.89	$0.00	Disclosure SEC source: 0001209191-21-042455 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Common Stock · 1,300 shares Expires 2031-06-17 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") will vest one (1) year from the June 17, 2021 grant date (the "Grant Date") subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document
June 10, 2021 Filed Jun 14, 2021 23:12 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	36,111	$0.00 Strike: $10.71	$0.00	Disclosure SEC source: 0001209191-21-040392 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,111 Underlying: Common Stock · 36,111 shares Expires 2031-06-10 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document
June 10, 2021 Filed Jun 14, 2021 23:12 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	10,115	$0.00	$0.00	Disclosure SEC source: 0001209191-21-040392 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,034 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantDeferred Stock Units · Derivative	699	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-037619 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,688 Underlying: Common Stock · 699 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. F1 · price: Upon the vesting of restricted stock units granted to Ms. McGlynn on June 1, 2020, Ms. McGlynn deferred the receipt of 699 shares of common stock and received instead 699 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 699 shares of common stock in exchange for an equal number of deferred stock units. F2 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. F2 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Disposition to issuerCommon Stock	699	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-037619 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,099 F1 · price: Upon the vesting of restricted stock units granted to Ms. McGlynn on June 1, 2020, Ms. McGlynn deferred the receipt of 699 shares of common stock and received instead 699 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 699 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document
May 03, 2021 Filed May 5, 2021 22:01 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	10,000	$0.00 Strike: $7.51	$0.00	Disclosure SEC source: 0001209191-21-030441 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document
May 03, 2021 Filed May 5, 2021 22:01 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	SaleCommon Stock	10,000	$10.27	$102,704.00	Disclosure SEC source: 0001209191-21-030441 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,919 F1 · kind: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.24 to $10.39 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 03, 2021 Filed May 5, 2021 22:01 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	10,000	$7.51	$75,100.00	Disclosure SEC source: 0001209191-21-030441 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2021 Filed May 4, 2021 20:17 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantStock Option (Right to Buy) · Derivative	3,034	$0.00 Strike: $217.20	$0.00	Disclosure SEC source: 0001209191-21-029861 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,034 Underlying: Common Stock · 3,034 shares Expires 2031-04-30 F2 · derivative.exercise_date: Fully vested. Read SEC document
May 01, 2021 Filed May 4, 2021 20:17 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	921	$0.00	$0.00	Disclosure SEC source: 0001209191-21-029861 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,798 F1 · shares: Restricted stock unit award that vests on the first anniversary of the grant date. Read SEC document
December 07, 2020 Filed Dec 9, 2020 23:01 UTC	NOVAVAX INC NVAX · Entity 4632	GrantStock Option (Right to buy) · Derivative	7,700	$0.00 Strike: $123.12	$0.00	Disclosure SEC source: 0001209191-20-062595 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2030-12-07 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, will vest one (1) year from the December 7, 2020 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document
September 30, 2020 Filed Oct 1, 2020 17:50 UTC	Air Products & Chemicals, Inc. APD · Entity 2983	GrantPhantom Stock · Derivative	194.3437	$293.86 Strike: $0.00	$57,109.84	Disclosure SEC source: 0001225208-20-011934 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,813.6292 Underlying: Common Stock · 194.3437 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan. F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document
August 25, 2020 Filed Aug 26, 2020 20:14 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GiftCommon Stock	3,707	$0.00	$0.00	Disclosure SEC source: 0001209191-20-048388 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877 F1 · kind: This transaction represents a charitable donation effective August 25, 2020. Read SEC document
June 30, 2020 Filed Jul 2, 2020 17:24 UTC	Air Products & Chemicals, Inc. APD · Entity 2983	GrantPhantom Stock · Derivative	238.0073	$238.61 Strike: $0.00	$56,790.92	Disclosure SEC source: 0001225208-20-009436 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,619.2855 Underlying: Common Stock · 238.0073 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan. F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:54 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	18,574	$0.00 Strike: $12.81	$0.00	Disclosure SEC source: 0001209191-20-035003 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,574 Underlying: Common Stock · 18,574 shares Expires 2030-06-04 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:54 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	5,855	$0.00	$0.00	Disclosure SEC source: 0001209191-20-035003 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,919 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document
June 01, 2020 Filed Jun 3, 2020 20:35 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantStock Option (Right to Buy) · Derivative	2,264	$0.00 Strike: $286.27	$0.00	Disclosure SEC source: 0001209191-20-034048 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,264 Underlying: Common Stock · 2,264 shares Expires 2030-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document
June 01, 2020 Filed Jun 3, 2020 20:35 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	699	$0.00	$0.00	Disclosure SEC source: 0001209191-20-034048 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,584 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document
April 17, 2020 Filed Apr 20, 2020 20:57 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	10,000	$0.00 Strike: $2.81	$0.00	Disclosure SEC source: 0001209191-20-025089 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of these options were fully vested and exercisable as of April 17, 2020. Read SEC document
April 17, 2020 Filed Apr 20, 2020 20:57 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	SaleCommon Stock	10,000	$11.00	$110,000.00	Disclosure SEC source: 0001209191-20-025089 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,064 F1 · kind: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
April 17, 2020 Filed Apr 20, 2020 20:57 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	10,000	$2.81	$28,100.00	Disclosure SEC source: 0001209191-20-025089 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 31, 2020 Filed Apr 2, 2020 15:13 UTC	Air Products & Chemicals, Inc. APD · Entity 2983	GrantPhantom Stock · Derivative	236.7099	$206.53 Strike: $0.00	$48,887.70	Disclosure SEC source: 0001225208-20-005835 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,381.2782 Underlying: Common Stock · 236.7099 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan. F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document
January 23, 2020 Filed Jan 24, 2020 17:37 UTC	Air Products & Chemicals, Inc. APD · Entity 2983	GrantPhantom Stock · Derivative	630.1462	$238.04 Strike: $0.00	$150,000.00	Disclosure SEC source: 0001225208-20-001102 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,144.5683 Underlying: Common Stock · 630.1462 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan. F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document
January 09, 2020 Filed Jan 10, 2020 22:34 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	20,000	$0.00 Strike: $3.32	$0.00	Disclosure SEC source: 0001209191-20-003096 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2020-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of these options were fully vested and exercisable as of January 9, 2020. Read SEC document
January 09, 2020 Filed Jan 10, 2020 22:34 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	SaleCommon Stock	20,000	$10.00	$200,000.00	Disclosure SEC source: 0001209191-20-003096 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,064 F1 · kind: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
January 09, 2020 Filed Jan 10, 2020 22:34 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	20,000	$3.32	$66,400.00	Disclosure SEC source: 0001209191-20-003096 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.